前列腺癌中度大分割放疗的急性和晚期毒性模式:系统综述与Meta分析
该系统综述与Meta分析纳入17项前瞻性研究、7796例局限期前列腺癌患者,评估中度大分割放疗(2.5-3.4 Gy/次)的急性毒性,并对10项含对照组的研究进行Meta分析。汇总结果显示,大分割放疗较常规分割急性≥2级胃肠毒性风险增加6.3%(95%CI 2.0%-10.6%),急性≥2级泌尿毒性和晚期毒性未显著增加。仅2/17项研究报告了毒性管理数据。
要点
- 大分割放疗较常规分割急性≥2级胃肠毒性风险增加6.3%(95%CI 2.0%-10.6%)。
- 急性≥2级泌尿毒性和晚期胃肠、泌尿毒性在大分割与常规分割间无显著差异。
- 仅2/17项研究报告了毒性管理(药物、干预)数据。
核心结论
- 大分割放疗与急性胃肠症状增加相关,需要充分的监测和管理。
- 关于毒性管理的报告非常有限。
- 汇总的晚期胃肠和泌尿毒性在大分割与常规分割之间显示相似水平。
研究设计与样本
- 按PRISMA指南进行的系统综述与Meta分析,检索截至2022年6月发表的研究。
- 共纳入17项前瞻性研究,包含7796例局限期前列腺癌患者,报告中度大分割(2.5-3.4 Gy/次)的急性毒性。
- 对10/17项含对照组(常规分割)的研究进行Meta分析,包括晚期毒性率的评估。
- 随机对照试验采用Cochrane偏倚评估工具,非随机对照试验采用Newcastle-Ottawa偏倚评估工具。
主要发现
- 汇总结果显示,大分割较常规分割急性≥2级胃肠毒性风险增加6.3%(风险差95%CI 2.0%-10.6%)。
- 急性≥2级泌尿毒性和晚期毒性未显著增加。
- 纳入研究的总体偏倚风险评估显示Meta分析为低风险。
- 毒性管理(药物、干预)数据仅在2/17项研究中有报告。
关键数值与推荐
- 中度大分割放疗剂量分割范围为2.5-3.4 Gy/次。
- 急性≥2级胃肠毒性风险差为6.3%(95%CI 2.0%-10.6%),大分割高于常规分割。
临床怎么用
- 大分割放疗与急性胃肠症状增加相关,原文结论指出需要充分的监测和管理。
- 原文指出关于毒性管理的报告非常有限。
局限性
- 毒性管理(药物、干预)数据仅在2/17项研究中有报告,相关报告非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Moderate hypofractionated (HF) radiotherapy is becoming the new standard in radiotherapy for prostate cancer patients. It is established as safe, but it might be associated with increased acute toxicity levels. We conducted a systematic review on moderate HF to establish acute toxicity levels and their required clinical management; late toxicity was reported as a secondary outcome. MATERIAL AND METHODS: Using PRISMA guidelines, we conducted a systematic review for studies published until June 2022. We identified 17 prospective studies, with 7796 localised prostate cancer patients, reporting acute toxicity of moderate hypofractionation (2.5-3.4 Gy/fraction). A meta-analysis was done for 10/17 studies with a control arm (standard fractionation (SF)), including evaluation of late toxicity rates. We used Cochrane bias assessment and Newcastle-Ottawa bias assessment tools for randomized controlled trials (RCTs) RCT and non-RCTs, respectively. RESULTS: Pooled results showed that acute grade ≥ 2 gastro-intestinal (GI) toxicity was increased by 6.3 % (95 % CI for risk difference = 2.0 %-10.6 %) for HF vs SF. Acute grade ≥ 2 Genito-urinary (GU) and late toxicity were not significantly increased. The overall risk of bias assessment revealed a low risk in the meta-analysis of included studies. Data on management of toxicity (medication, interventions) was only reported in 2/17 studies. CONCLUSION: HF is associated with increased acute GI symptoms, needing adequate monitoring and management. Reports on toxicity management were very limited. Pooled late GI and GU toxicity showed similar levels for SF and HF.
引用
- Sinzabakira F, Brand V, Heemsbergen WD, et al. Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2023. PMID: 36992969. doi:10.1016/j.ctro.2023.100612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。